Asciminib RMP Study
ConditionChronic Myeloid Leukemia
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-100
SponsorNovartis Pharmaceuticals
About this trial
This study is a prospective, open-label, multi-center, non-comparative, observational study to assess safety and effectiveness of Asciminib in the real-world clinical setting in Korean Chronic myeloid leukemia (CML) patients.
Eligibility criteria
Qualifiers
Adult patients diagnosed with Ph+ CP-CML and currently receiving or going to receive Scemblix® treatment according to locally approval label
Patients who are willing to provide written informed consent prior to study enrollment
Disqualifiers
Patients with contraindication according to locally approved label of Scemblix®
Patients who receive or are going to receive any investigational medicine during the observation period
Trial design
Treatments tested in this trial
- Asciminib
Treatment groups
600 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov